FDA approved lixisenatide (Adlyxin, Sanofi-Aventis), a once-daily mealtime GLP-1 receptor agonist injection for type 2 diabetes, which will compete against the once-weekly pen dulaglutide (Trulicity, Eli Lilly) and the injectable liraglutide (Victoza, Novo Nordisk).
New data from Novo Nordisk will help its Victoza (liraglutide) for type 2 diabetes better compete against Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin).
Victoza significantly reduced the combined incidence of heart attack, stroke and cardiovascular death in high-risk Type 2 diabetes patients, according to Novo Nordisk
Consumer advocacy group Public Citizen said this week that the Food and Drug Administration (FDA) must stop direct-to-consumer advertisements that market several “dangerous” diabetes medications for weight loss or blood pressure reduction.
On the 1-year anniversary of the first G8 summit on dementia, new funding has been announced for a study to research the use of tadalafil (Adcirca, Cialis; Eli Lilly), an erectile dysfunction drug, for the treatment of vascular dementia.
The role of ophthalmologists will become increasingly more vital in the management of type 2 diabetes as the numbers of patients with the disease is projected to double by 2030. Exenatide may prove to be an important adjunct to current oral anti-diabetes drugs.